Bormioli Pharma achieves 45% sustainable materials in eco-positive range

25 April 2024

Bormioli Pharma, a leading player in the pharmaceutical packaging industry, has unveiled its third edition of the Sustainability Report, showcasing significant strides towards environmental, social, and governance (ESG) goals. The report underscores Bormioli Pharma’s commitment to fostering sustainable growth within the communities it serves and supporting the pharmaceutical sector’s transition towards eco-friendly solutions.



One of the standout initiatives highlighted in the report is Bormioli Pharma‘s decision to undergo external assurance of its Sustainability Report, two years ahead of legal obligations. A proactive approach that underscores the company’s dedication to transparency and accountability in its sustainability efforts! Additionally, the reinforcement of the ESG team and Governance reflects Bormioli Pharma’s commitment to robust ESG policies and practices, aligning with emerging regulatory directives such as the EU’s Corporate Sustainability Reporting Directive (CSRD).

Setting ambitious sustainability targets, Bormioli Pharma aims to reduce carbon intensity by 30% and water withdrawal intensity by 41% by 2030, compared to the 2021 baseline. Notably, the company has made significant strides in increasing the share of sustainable materials in its products, with the EcoPositive range leading the charge. In 2023, Bormioli Pharma achieved a remarkable milestone, reaching 45% sustainable materials in sold products, marking a 15% increase compared to the previous year and edging closer to its 50% target by 2025.

Andrea Lodetti, CEO of Bormioli Pharma, emphasized the company’s role as a catalyst for responsible growth within the pharmaceutical industry.

In 2023, we have worked energetically to be an important driver of responsible growth, remarking our role as a partner of the pharmaceutical industry in developing increasingly widespread, effective, and sustainable medical practices.

He highlighted the expansion of the EcoPositive sustainable packaging offering as a tangible step towards supporting the EU’s sustainable packaging objectives.


Bormioli Pharma’s ESG commitment extends beyond environmental stewardship to encompass diversity and inclusion initiatives. With the aim of fostering a culture of diversity and inclusion across the organization, the company has set a target to train 95% of its employees on these topics by 2025.

Furthermore, the report underscores Bormioli Pharma’s commitment to responsible sourcing and supply chain management. The company aims to assess 90% of its suppliers on the international EcoVadis platform by 2026, ensuring alignment with its high ESG standards and fostering responsible purchasing choices.

Despite the challenges posed by the evolving business landscape, Bormioli Pharma’s economic performance in 2023 showcased resilience and growth, with an impressive 18% increase in revenues compared to the previous year. This reaffirms the efficacy of the company’s strategic choices and underscores its ability to generate long-term value while prioritizing the well-being of people, the environment, and society. By embracing sustainability as a core business imperative, the company is poised to continue its journey towards a more sustainable and inclusive future.